Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
A run of bad news leaves investors questioning Wave Life Sciences’ ability to deliver on its promises.
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Second Sight’s second product might lead the company to second place in the market.
The Vitrakvi follow-on LOXO-195 yields results backing both the rationale behind its development and Bayer’s decision to take on full rights.
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.